Here's a concise summary for Aarti Drugs Limited: **1. Business Performance:** Aarti Drugs reported steady Q3 FY26 results with total revenue up 8% YoY to ₹603 Crore.

While EBITDA saw a 10% YoY dip to ₹56 Crore (margin 9.3%), Net Profit (PAT) surged 58% YoY to ₹41 Crore (margin 6.7%), boosted by a tax refund.

For the nine-month period, revenue grew 8% to ₹1,847 Crore, and PAT increased 49% to ₹140 Crore.

The API segment remains the largest contributor to revenue. **2. Growth Drivers or Strategy:** The company is actively operationalizing growth projects and focusing on backward integration.

Its Sayakha plant for methyl amines is at 30% capacity, targeting 50% by March/April 2026, aiming for 100% self-reliance for Metformin in 6-8 months.

The Salicylic Acid plant in Tarapur reached ~300 tonnes per month, reducing import dependence, with further downstream expansion planned. **3. Recent Developments:** Regulatory certifications and approvals are progressing as planned, including preparations for European approvals.

Sales momentum is picking up, with encouraging traction observed in January, indicating a positive trend for coming quarters. **4. Key Financial Metrics:** Q3 FY26: Revenue +8% YoY, PAT +58% YoY, EBITDA -10% YoY.

9M FY26: Revenue +8% YoY, PAT +49% YoY, EBITDA +9% YoY.

Earnings Per Share (EPS) for Q3 was ₹4.44. **5. Management Commentary / Outlook:** Management notes an inflection point with stable prices and increasing volumes after past realization pressure.

The company is prioritizing operational efficiency, margin improvement, and capacity ramp-up while maintaining capital discipline.